![](/images/graphics-bg.png)
Immunotherapy- (Blinatumomab-) Related Lineage Switch of KMT2AAFF1 Rearranged B-Lymphoblastic Leukemia into Acute Myeloid LeukemiaMyeloid Sarcoma and Subsequently into BMyeloid Mixed Phenotype Acute Leukemia
Joint Authors
Peterson, Jess F.
He, Rui R.
Nayer, Zacharia
Hogan, Matthew
Cuevo, Raymund S.
Woodward, Kimberly
Heyer, David
Curtis, Christine A.
Source
Issue
Vol. 2019, Issue 2019 (31 Dec. 2019), pp.1-4, 4 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2019-12-07
Country of Publication
Egypt
No. of Pages
4
Main Subjects
Abstract EN
The presence of KMT2A/AFF1 rearrangement in B-lymphoblastic leukemia (B-ALL) is an independent poor prognostic factor and has been associated with higher rate of treatment failure and higher risk of linage switch under therapy.
Blinatumomab has shown promising therapeutic results in refractory or relapsed B-ALL; however, it has potential risk of inducing lineage switch, especially in KMT2A/AFF1 rearranged B-ALL into acute myeloid leukemia and/or myeloid sarcoma.
We report a 40-year-old female with KMT2A/AFF1-rearranged B-ALL that was refractory to conventional chemotherapy.
Following administration of blinatumomab, she developed a breast mass proven to be myeloid sarcoma, in addition to bone marrow involvement by AML.
Approximately six weeks after cessation of blinatumomab, a repeat bone marrow examination revealed B/myeloid MPAL.
American Psychological Association (APA)
He, Rui R.& Nayer, Zacharia& Hogan, Matthew& Cuevo, Raymund S.& Woodward, Kimberly& Heyer, David…[et al.]. 2019. Immunotherapy- (Blinatumomab-) Related Lineage Switch of KMT2AAFF1 Rearranged B-Lymphoblastic Leukemia into Acute Myeloid LeukemiaMyeloid Sarcoma and Subsequently into BMyeloid Mixed Phenotype Acute Leukemia. Case Reports in Hematology،Vol. 2019, no. 2019, pp.1-4.
https://search.emarefa.net/detail/BIM-1136659
Modern Language Association (MLA)
He, Rui R.…[et al.]. Immunotherapy- (Blinatumomab-) Related Lineage Switch of KMT2AAFF1 Rearranged B-Lymphoblastic Leukemia into Acute Myeloid LeukemiaMyeloid Sarcoma and Subsequently into BMyeloid Mixed Phenotype Acute Leukemia. Case Reports in Hematology No. 2019 (2019), pp.1-4.
https://search.emarefa.net/detail/BIM-1136659
American Medical Association (AMA)
He, Rui R.& Nayer, Zacharia& Hogan, Matthew& Cuevo, Raymund S.& Woodward, Kimberly& Heyer, David…[et al.]. Immunotherapy- (Blinatumomab-) Related Lineage Switch of KMT2AAFF1 Rearranged B-Lymphoblastic Leukemia into Acute Myeloid LeukemiaMyeloid Sarcoma and Subsequently into BMyeloid Mixed Phenotype Acute Leukemia. Case Reports in Hematology. 2019. Vol. 2019, no. 2019, pp.1-4.
https://search.emarefa.net/detail/BIM-1136659
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1136659